Recent Finacing
Recent Raise
Abpro develops antibody therapeutics using its DiversImmune™ synthetic-biology antibody discovery and engineering platform, focusing on bispecific immuno-oncology and ophthalmology candidates and partnering with biopharma and academic centers.
